LOS ANGELES, CA / ACCESSWIRE / December 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) has been assigned a consensus rating of “Buy” from the eight research firms ...

SAN FRANCISCO, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ: HUMA) and certain of its executives are now defendants in a class action lawsuit filed in the U.S. District Court for the ...

If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your ...

On Friday, Humacyte Inc (HUMA) stock saw a modest uptick, ending the day at $4.47 which represents a slight increase of $0.07 or 1.59% from the prior close of $4.4. The stock opened at $4.44 and ...

Humacyte, Inc.（纳斯达克股票代码：HUMA）的总裁、首席执行官兼董事Laura E. Niklason最近购买了1,797股公司普通股。这些股票的平均购买价格为每股4.44美元，总交易价值为7,978美元。此次交易后，Niklason直接持有243,851股。此外，她还通过The Niklason Living Trust和Ayabudge LLC等多个实体间接持有股份。

根据最近的披露，Humacyte, Inc. (NASDAQ:HUMA)的董事Brady W. Dougan报告出售了他在公司的大量持股。这些交易发生在11月18日至11月20日的三天期间，共涉及出售150万股Humacyte普通股。

When I first analyzed Humacyte in October 2022, its stock was trading at ~$4.65 a share and prospects looked encouraging for its then dubbed human acellular vessel (HAV) platform candidates.

DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable ...

Class Action, Consumer Services, GlobeNewswire, Law & Legal Issues | NEW YORK, Nov. 30, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law F ...

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers ...

Insiders who acquired US$775.1k worth of Humacyte, Inc.'s ( NASDAQ:HUMA ) stock at an average price of US$6.64 in ...